Cassava Sciences Inc. (SAVA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cassava Sciences Inc. (SAVA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.63

-0.10 (-3.66%)

At close: Jan 14, 2025, 3:59 PM

2.60

-0.95%

Pre-market Jan 15, 2025, 06:55 AM EST

undefined% (undefined)

Bid	2.59
Market Cap	126.29M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.38
PE Ratio (ttm)	-1.9
Forward PE	n/a
Analyst	Hold

Ask	2.61
Volume	1,767,905
Avg. Volume (20D)	5,612,470
Open	2.77
Previous Close	2.73
Day's Range	2.57 - 2.78
52-Week Range	2.23 - 42.20
Beta	undefined

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sci...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 14, 2000

Employees 29

Stock Exchange NASDAQ

Ticker Symbol SAVA

Website https://www.cassavasciences.com

Analyst Forecast

According to 3 analyst ratings, the average rating for SAVA stock is "Hold." The 12-month stock price forecast is $111.5, which is an increase of 4147.62% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-10.93%

Cassava Sciences shares are trading lower after HC... Unlock content with Pro Subscription

1 month ago · Source

-83.76%

Cassava Sciences shares are trading lower after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study.

News

2 weeks ago · https://www.marketscreener.com

SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

NEW YORK, Dec. 28, 2024 /PRNewswire/ -- aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of se...